Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose

Exclusion Criteria

• •General criteria:
• •Pregnant women, breastfeeding
• •Hypersensitivity to the active substance or any of its excipients
• •Hypersensitivity to the products of Chinese hamster ovary cells or other human or humanized recombinant antibodies
• •Inability to undergo medical monitoring due to reasons geographical, social or psychological
• •Patient under guardianship
• •Patient included in another biomedical research protocol
• •Related to medical history criteria:
• •Uncontrolled hypertension ( systolic BP \> or = 150 mmHg and / or Diastolic BP \> or = 100 mmHg)
• •Thrombocytopenia \<100 G / L
• •Taking NSAIDs within ten days prior to inclusion
• •Anticoagulant therapy or thrombolytic within 28 days before inclusion
• •Tumor, genetic predisposition to bleeding, coagulopathy , patient receiving treatment full anticoagulant dose for an event thromboembolism prior to inclusion
• •Major surgery within 28 days prior to inclusion
• •History of thromboembolic disease within 6 months prior to enrollment
• •Arteriovenous malformation localized to the brain, liver or lung on scanner older than 5 years
• •History of heart failure
• •Patients with proteinuria / creatinine greater than 2g / g